SansRosa, a Philadelphia-area start-up focused on dermatological conditions, is reprofiling a group of alpha agonists for use as treatments for rosacea and other disorders. The firm was founded in late 2002 and has so far raised $500,000 from Bioadvance to support its efforts.
100 Front Street #1350
West Conshohocken, PA 19428
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.
As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?
With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.
After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.